dr. peeters discusses the efficacy and safety of panitumumab versus cetuximab in colorectal cancer
Published 9 years ago • 787 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
1:51
dr. peeters discusses the frequency of s492r mutations following egfr inhibition in mcrc
-
1:05
dr. peeters on the utility of aflibercept in advanced colorectal cancer
-
4:28
introduction: bevacizumab versus cetuximab in metastatic colorectal cancer
-
1:24
dr. peeters on the future of colorectal cancer
-
5:27
epoc studies: preoperative cetuximab in kras wild-type colorectal cancer
-
9:00
first- and later-line use of panitumumab in metastatic colorectal cancer
-
1:08
dr. weinberg on the role of cetuximab in metastatic crc
-
1:56
dr. peeters on kras/nras mutations in mcrc
-
1:20
dr. muro on results of paff-k study in colorectal cancer
-
11:36
panitumumab, regorafenib, and ziv-aflibercept in metastatic colorectal cancer
-
7:36
emccc 2010: the use of panitumumab to treat colorectal cancer
-
1:46
dr. peeters discusses kras/nras mutations in mcrc
-
0:48
dr. marc peeters on the aflibercept toxicity profile
-
2:42
dr. bekaii-saab discusses an analysis of bevacizumab or cetuximab for crc
-
1:37
panitumumab data presented at esmo 2016: depth of response and selecting the right patients
-
7:19
safety of sotorasib and panitumumab in advanced kras p.g12c-mutated colorectal cancer
-
5:25
second-line and salvage treatment of metastatic colorectal cancer
-
7:32
considerations when selecting an egfr inhibitor in metastatic colorectal cancer
-
1:50
dr. benson on sequencing strategies with cetuximab in crc